Search
Zelquistinel
go.drugbank.com/drugs/DB19336InvestigationalZelquistinel is under investigation in clinical trial NCT06547489 (GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder).
Ingenol disoxate
go.drugbank.com/drugs/DB15109InvestigationalIngenol disoxate is under investigation in clinical trial NCT02120456 (Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk
Andrographolide
go.drugbank.com/drugs/DB05767InvestigationalThe herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases.
Norclozapine
go.drugbank.com/drugs/DB05766InvestigationalACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. … It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.
CK0802
go.drugbank.com/drugs/DB15866Investigational[L16358] On the surface of these T-Reg cells, T-cell lung homing markers are expressed. … CK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching.
Clobetasol
go.drugbank.com/drugs/DB11750ApprovedInvestigationalWithdrawnClobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.
Products: CLARELUX 500UG/G SCHAU, CLARELUX 500UG/G SCHAUMAvexitide
go.drugbank.com/drugs/DB14806ApprovedInvestigationalWithdrawnAvexitide is under investigation in clinical trial NCT02996812 (Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia).
MK-0354
go.drugbank.com/drugs/DB05939InvestigationalIt targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin. … MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.
Pinatuzumab vedotin
go.drugbank.com/drugs/DB15432InvestigationalPinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or … Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)).
AGRO100
go.drugbank.com/drugs/DB04998InvestigationalAGRO100 is an oligonucleotide that functions as an aptamer and binds to nucleolin, a protein found intranuclear in all cells, but uniquely expressed on the surface of tumor cells. … Pre-clinical testing demonstrates that the AGRO100 inhibition of nucleolin function produces anti-cancer effects against multiple types of the disease, including lung, prostate, breast, cervical, and colon